

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>		
				Application Number	10/510,677	
				Filing Date	2003-04-09	
				First Named Inventor	M. Parrington	
				Art Unit	1642	
				Examiner Name	Sean E. Aeder	
Sheet	1	of	1	Attorney Docket No: API-01-20-US		

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A94	4,923,808	1990-05-08	Matteucci, et al.	Entire document
	A95	6,407,063	2002-06-18	Luiten, et al.	Entire document

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	B10	WO 98/29556A1	1998-07-09	The Wistar Institute	Entire document	
	B11	WO 99/46992A1	1999-09-23	Genzyme Corporation	Entire document	
	B12	WO 99/46988	1998-03-20	Genzyme Corporation	Entire document	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	C28	BERINSTEIN, et al. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. J. Clin. Oncol. 20(8): 2197-2207 (2002)	
	C29	DUBENSKY, et al. Delivery Systems for Gene-Based Vaccines. Mol. Med. 6(9): 723-732 (2000)	
	C30	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. Vaccine, vol. 15, issue 6/7, pp. 759-768 (1997)	
	C31	LEITNER, et al. Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors. Cancer Res. 60: 51-55 (2000)	
	C32	MARSHALL, J. Carcinoembryonic Antigen-Based Vaccines. Semin. Oncol. (suppl. 8): 30-36 (2003)	
	C33	PARDOLL, D.M. Cancer vaccines. Nat. Med. 4: 525-531 (1998)	
	C34	PARMIANI, et al. Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J. Natl. Cancer Inst. 94: 805-818 (2002)	
	C36	VAN DER BURG, et al. Induction of p53-Specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. Clin. Cancer Res. 8: 1019-1027 (2002)	

EXAMINER

/Sean Aeder/ (03/05/2010)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.A./